WallStSmart

HealthEquity Inc (HQY)vs10X Genomics Inc (TXG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HealthEquity Inc generates 109% more annual revenue ($1.34B vs $638.78M). HQY leads profitability with a 17.2% profit margin vs -3.5%. HQY earns a higher WallStSmart Score of 66/100 (B-).

HQY

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 7.5Value: 6.7Quality: 8.0
Piotroski: 7/9Altman Z: 1.86

TXG

Avoid

20

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 1.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HQYUndervalued (+57.6%)

Margin of Safety

+57.6%

Fair Value

$181.42

Current Price

$104.97

$76.45 discount

UndervaluedFair: $181.42Overvalued
TXGUndervalued (+68.1%)

Margin of Safety

+68.1%

Fair Value

$60.02

Current Price

$47.86

$12.16 discount

UndervaluedFair: $60.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HQY2 strengths · Avg: 8.0/10
Operating MarginProfitability
29.3%8/10

Strong operational efficiency at 29.3%

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

TXG1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Areas to Watch

HQY2 concerns · Avg: 4.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.864/10

Grey zone — moderate risk

TXG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

Revenue GrowthGrowth
-2.6%2/10

Revenue declined 2.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : HQY

The strongest argument for HQY centers on Operating Margin, EPS Growth. Profitability is solid with margins at 17.2% and operating margin at 29.3%. PEG of 1.44 suggests the stock is reasonably priced for its growth.

Bull Case : TXG

The strongest argument for TXG centers on Debt/Equity.

Bear Case : HQY

The primary concerns for HQY are P/E Ratio, Altman Z-Score.

Bear Case : TXG

The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

HQY profiles as a mature stock while TXG is a turnaround play — different risk/reward profiles.

TXG carries more volatility with a beta of 2.04 — expect wider price swings.

HQY is growing revenue faster at 7.2% — sustainability is the question.

HQY generates stronger free cash flow (97M), providing more financial flexibility.

Bottom Line

HQY scores higher overall (66/100 vs 20/100), backed by strong 17.2% margins. TXG offers better value entry with a 68.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HealthEquity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HealthEquity, Inc. provides technology-enabled service platforms to consumers and employers in the United States. The company is headquartered in Draper, Utah.

10X Genomics Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Want to dig deeper into these stocks?